|Bid||44.28 x 1300|
|Ask||44.33 x 900|
|Day's Range||44.14 - 44.56|
|52 Week Range||39.30 - 66.04|
|Beta (3Y Monthly)||0.37|
|PE Ratio (TTM)||13.24|
|Earnings Date||Oct 31, 2019|
|Forward Dividend & Yield||3.36 (7.72%)|
|1y Target Est||52.86|
NEW ORLEANS, Oct. 18, 2019 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending.
Canadian cannabis producer Cronos Group is "a new king in the north," an analyst said in upgrading the stock.
NEW YORK, NY / ACCESSWIRE / October 18, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Altria Group, Inc. (“Altria” or the “Company”) (NYSE: MO) and certain of its officers, on behalf of shareholders who purchased Altria securities between February 8, 2019 and August 12, 2019, both dates inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
Shares of Altria Group Inc. rose before paring those gains, after Citigroup upgraded the stock to neutral from sell and said it expects cigarettes will benefit from the negative publicity and regulatory crackdown that has been sparked by the vaping-related lung illness that has swept the U.S. The disease has killed at least 33 people and sickened 1,479, according to the latest data from the Centers for Disease Control and Prevention. "The stock is below our target and we think it no longer looks expensive relative to overseas peers," analysts wrote in a note to clients. "Unfortunately we expect the short-term newsflow (on FDA regulation and earnings) to be difficult." Citigroup is expecting the FDA's flavor ban to be harsh and to include a ban on mint and menthol, posing a challenge to Juul, the e-cigarette maker in which Altria owns a 35% stake. Altria is expected to report third-quarter earnings on Oct. 31 and Citi is expecting a 7% decline in underlying cigarette volumes, but an 11% decline in shipments. Altria stock was last down 0.2% and has fallen 11% in 2019, while the Dow Jones Industrial Average , which counts it a member, has gained 15% and the S&P 500 has gained 19%.
NEW YORK, NY / ACCESSWIRE / October 18, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...
Citigroup analyst Adam Spielman raised his rating on Altria stock to Neutral from Sell, and notes that negative headlines about vaping may boost sales of traditional cigarettes.
NEW YORK, NY / ACCESSWIRE / October 18, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Altria Group, Inc. ("Altria" or the "Company") ...
It's been a hard year for marijuana firms and their investors. The industry has been wracked with worries about health concerns, waning demand and regulatory tie-ups. Naturally, this has taken a toll on marijuana stock prices.Aurora Cannabis (NYSE:ACB) is a prime example of a pot stock that's been hammered over the past 12 months. ACB stock has fallen 67% from where it was a year ago and many are speculating that the industry hasn't bottomed yet.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Troubled IndustryOne of the big reasons the industry is struggling right now is the slow-moving legalization process in Canada. The government is struggling to get through a backlog of licensing requests. That means companies that want to operate within Canada's legal marijuana market sometimes have to wait over a year for a permit.Canada's so-called "Cannabis 2.0" is slated to begin on October 17. During that time, the nation will legalize vaping products, edibles and cannabis-infused beverages. On the surface, that looks like a near-term catalyst for ACB. But if the nation's last round of marijuana legalization is anything to go by, we might be waiting a long time to see the benefits. * The 7 Best Penny Stocks to Buy On top of that, the marijuana industry is bumping up against health concerns as well. Vaping has been linked to 33 deaths across the U.S. and thousands of "lung injury cases." What's worse is that the Centers for Disease Control and Prevention says the majority of those patients have a history of using products that contain THC, the psychoactive chemical found in marijuana. Issues Involving ACB StockOf course, the industry-wide issues with obtaining legal permits put all marijuana firms on a level playing field. However, the vaping concerns weigh heavily on ACB stock as the firm is making big bets on the future of that industry. Management has consistently pointed to vaping as an area of focus. So, if regulators clamp down to avoid health problems, it could have a negative impact on Aurora stock.There are many out there, though, who look at the vaping issues as little more than a blip on the radar. After all, cigarettes contribute heavily to a host of terminal illnesses, but that market is still open for business. That's true, but the vaping concerns aren't the only problems Aurora stock is facing.Aside from its vaping bets, investors purchasing ACB stock are taking on some risky financials as well.The firm is in need of cash to continue funding its growth plans and likely has nowhere to turn aside from capital markets. Next March, ACB will have 230 million CAD worth of convertible debt to pay off. If the firm's share price is still in the gutter, it's doubtful the lenders will be willing to take the stock-conversion option. That means Aurora will likely take on even more debt, a worrying prospect for shareholders. The Silver Lining for Aurora StockOverall, Aurora Cannabis stock looks like a pretty shaky investment. It's uncertain financials and decision to focus on vaping makes it a risky bet. However, the firm does have some things going for itself.Aurora's sales make it the largest player in Canada and margins have been improving as costs fall. Plus, the firm has finally outlined plans to enter the CBD market, which is poised to explode in the coming years.ACB has aligned itself with Ultimate Fighting Championship in order to test whether CBD is effective in treating pain. The results of the study will eventually help Aurora develop a line of topical CBD products aimed at athletes. Potential PartnershipAnother potential positive for ACB stock is the fact that the firm is making its way as a leader in the cannabis industry without the help (or control) of a larger partner from another industry. The firm's rivals Canopy Growth (NYSE:CGC) and Cronos Group (NASDAQ:CRON) have inked deals with Constellation Brands (NYSE:STZ) and Altria (NYSE:MO), respectively.Aurora, on the other hand, is still flying solo. If everything pans out, that would be an advantage for long-term ACB stockholders as both Cronos and Canopy are likely to be bought out by their partners before they realize their full potential.Not everyone believes going it alone is the best option. Larger partners mean deeper pockets and better funding, which is something Aurora Cannabis stock could use right now. Also, the cross-industry tie is likely to help as marijuana products bleed into other consumer product lines in the future.There's also some question as to why big names aren't aggressively pursuing Aurora. The firm brought on infamous strategic advisor Nelson Peltz in what many believed was an effort to secure a cross-industry partnership. The Bottom LineACB stock doesn't look like it's heading to zero, but it might get close. Moreover, 20 years from now the stock might be a winner, but for now I'd remain on the sidelines.If you've got time and you're a sucker for a large risk/reward payoff, Aurora stock could be a winner. However, for now I think your capital is better deployed until there's a clearer picture of the firm's future on the table.As of this writing, Laura Hoy did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Penny Stocks to Buy * 7 Bank Stocks to Avoid Now at All Costs * The 10 Best Mutual Funds for Your 401k The post This Isnat the Time to Buy Aurora Cannabis Stock appeared first on InvestorPlace.
Altria (NYSE:MO) stock again finds itself hurt by negative headlines. The controversy over its vaping product, Juul, has led investors to dump MO stock. As a result, it now trades close to its 52-week lows.Source: Kristi Blokhin / Shutterstock.com However, as a result of the concerns surrounding Juul, Altria stock trades at a relative discount and now gives investors an unusually high payout near 7.75%. More importantly, the trading history of MO indicates that Altria stock could profit investors hugely at these levels. MO Stock has Long Prospered Amid Negative PublicityDespite the negative specter that has hung over tobacco stocks since for the 1960s, Altria stock tends to generate profits and generous dividends year after year with little fanfare. However, the negative publicity has returned in recent weeks. Its investment in Juul has come under fire as medical experts have linked vaping products to multiple hospital visits and a few deaths.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, as we have learned over the decades, investors have good reason to take any negative publicity about the tobacco industry with a grain of salt. The Surgeon General's report that first warned of the dangers of smoking came out in 1964. At that time, about 42% of Americans smoked cigarettes. Smoking was commonplace and permitted in most public areas. Altria stock (then known as Philip Morris Companies) was trading at the split-adjusted price of 13 cents per share.The Centers for Disease Control notes that smoking rates continue to fall. However, by 2016, only about 15.5% of the population smoked cigarettes. Now, smokers often struggle to find a public place where they can light their cigarettes. Despite this stigma on tobacco, the Altria stock price stands at around $44 per share, an increase of almost 340 times from 1964 levels. With the dividend at $3.36 per share, investors who have owned Altria stock since 1964 receive almost a 26-fold return annually on the payout alone! * 10 Hot Stocks Staging Huge Reversals That stock growth happened amid decades of negative publicity and billions in legal settlements. If all of that did not stop Altria stock from growing, I remain skeptical that the controversy surrounding vaping will damage the company long term. Juul Brings Both Pain and a Buy OpportunityInvestors should also remember that the investigations continue. This means they may not ultimately trace the illnesses directly to Juul. Also, even if Altria has to write off its $12.8 billion investment in Juul, the company's $1.8 billion stake in cannabis stock Cronos Group (NASDAQ:CRON) could still help the company. That investment gave Altria 45% of Cronos, with the option to take this stake as high as 55%. This should give Altria an alternate, fast-growing revenue source even if tobacco smoking rates continue to fall.Still, investors also need to consider the significant amount of short-term damage that vaping illnesses have caused. Altria stock has fallen by about one-third from the 52-week high it achieved almost a year ago. Concerns about Juul also likely sidelined the proposed merger with Philip Morris International (NYSE:PM).As a result, MO stock trades at a forward price-to-earnings (PE) ratio of around 9.8. This is well below the 16.4x average PE ratio Altria supported during the previous five years. Moreover, Wall Street projects profit growth of 5% in 2019 and 7.2% in the next fiscal year. This will not impress many investors, but it still should help maintain its periodic payout hikes. Though the company sometimes misses an annual dividend increase, it has hiked the payout annually for the last 10 years.This has also occurred despite a dividend yield that dramatically exceeds historical averages. Over the last five years, Altria stock produced an average return on its payout of about 4.3%. However, investors who buy today will see a cash return of about 7.75%. Bottom Line on Altria StockFrom a numbers perspective, Altria stock looks clearly like a buy. With a single-digit PE ratio and a growing, generous dividend yield, investors who buy MO stock now should profit from their decision long term. * 7 Dividend Stocks to Buy (With Brands You Can Find In Your Kitchen) In time, the controversy over Juul will fade from the headlines. However, the long-term average multiple has, and will, probably continue to lag the S&P 500 index. The established link between smoking and a variety of diseases creates a permanent worry about the cost of settlements and other costs. Moreover, many Americans have seen family and friends become sick and die prematurely due to tobacco use. For some of them, Altria stock is not a buy at any price. Investors need to continue to factor this sentiment into the MO stock price.However, MO trades at multiples well below its long-term averages and offers a huge dividend payout. If the lawsuits and anti-smoking crusades from previous decades did not stop Altria stock, I doubt vaping issues will either.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Penny Stocks to Buy * 7 Bank Stocks to Avoid Now at All Costs * The 10 Best Mutual Funds for Your 401k The post The History of Altria Stock Indicates That Now is the Time To Buy appeared first on InvestorPlace.
Juul has suspended the sale of non-tobacco and non-menthol flavors in the U.S., according to a company press release. Altria, a big investor in Juul, saw its stock gain more than 1% on Thursday.
(Bloomberg) -- Juul Labs Inc., the largest e-cigarette maker in the U.S., is suspending sales of most nicotine pod flavors nationwide, bending to pressure from officials and the public who said sugary flavors were hooking teens.Fruit and dessert flavors, which the company was selling to people over 21 through its website, are no longer available in the U.S. pending a review by the Food and Drug Administration, Juul said. It will continue selling mint, menthol and tobacco flavor pods in stores and online.The creators of Juul have said they designed e-cigarettes to help longtime smokers switch, but the popular devices have also introduced a generation of teens and young adults to nicotine. Scott Gottlieb, the former FDA commissioner who declared youth vaping an epidemic, said Juul’s decision to continue selling mint and menthol won’t solve the problem. “Mint is a candy flavor,” Gottlieb said. “A lot of the youth use has shifted to that flavor.”Juul said the new sales restriction comes out of a review led by the new chief executive officer, K.C. Crosthwaite, who joined last month from tobacco giant Altria Group Inc. As part of that review, Juul said last month it would stop all U.S. advertising, refrain from supporting a proposition to voters in San Francisco that would reverse an e-cigarette ban and stop lobbying the government about legislation related to flavors. Michael Bloomberg, the founder and majority owner of Bloomberg LP, funds anti-vaping advocacy initiatives, including one to defeat the San Francisco ballot measure.Shares of Altria, which sells Marlboro in the U.S. and is Juul’s largest shareholder, were up 1.2% to $44.05 at 2 p.m. in New York. “We must reset the vapor category by earning the trust of society and working cooperatively with regulators, policymakers, and stakeholders to combat underage use while providing an alternative to adult smokers,” Crosthwaite said in a statement.The new policy began Thursday and affects sales on its website of the flavors fruit, creme, mango and cucumber. Online purchases of the remaining flavors will continue to be screened by Juul’s age verification system.Juul had stopped the distribution of those flavors last November to physical retailers in the U.S., a move it made in anticipation of sales restrictions from the FDA on flavored e-cigarette products. That move led to a slight dip in sales, but the San Francisco-based company has largely recovered, thanks partly to international growth.In the U.S., Juul controls 70% of vape sales, according to market research firm IRI, which doesn’t track online sales. Investors valued Juul at $38 billion in December, before growing outrage in recent months led to the departure of its previous CEO.In September, Health and Human Services Secretary Alex Azar said that U.S. health monitors had seen a continuing rise in youth use, including of flavors like mint and menthol. He said the Trump administration’s goal was to ban those flavors and leave only tobacco-flavored e-cigarettes on the market.Juul is still evaluating which products and flavors to submit for regulatory approval in May, which means some of these flavors could return to shelves if the FDA approves them. Josh Raffel, a spokesman for Juul, said the company could also extend its temporary sales ban to other flavors, such as mint and menthol. “We continue to review our policies and practices in advance of FDA’s flavor guidance and have not made any final decisions,” he said.(Updates with market share data in the eighth paragraph.)To contact the authors of this story: Ellen Huet in San Francisco at firstname.lastname@example.orgDrew Armstrong in New York at email@example.comTo contact the editor responsible for this story: Mark Milian at firstname.lastname@example.org, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
NEW YORK, NY / ACCESSWIRE / October 17, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine ...
Juul Labs Inc. said Thursday that it will suspend online sales of non-tobacco, not-menthol-based flavors of e-cigarettes, including Mango, Creme, Fruit and Cucumber, in the U.S. The company had previously suspended all broadcast, print and digital product advertising in the U.S., and has refrained from lobbying the Trump administration on its draft flavor guidance. Sales of the flavored e-cigarettes were suspended at stores, but had still been only available at Juul.com, until today. "We must reset the vapor category by earning the trust of society and working cooperatively with regulators, policymakers, and stakeholders to combat underage use while providing an alternative to adult smokers," said Chief Executive K.C. Crosthwaite. Shares of Altria Inc. , which disclosed in December a $12.8 billion investment in Juul, rose 1.2% in afternoon trading, but has lost 10.9% year to date while the Dow Jones Industrial Average has gained 15.8% this year.
NEW YORK, NY / ACCESSWIRE / October 17, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Altria Group, Inc. ("Altria" or the "Company") (MO) and certain of its officers. The class action, filed in United States District Court, for the Eastern District of New York, and indexed under 19-cv-05579, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired Altria securities between December 20, 2018 and September 24, 2019, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
E-cigarette maker Juul Labs Inc said on Thursday it will completely halt U.S. sales of all flavors except tobacco, mint and menthol, as the company faces heightened scrutiny from regulators, lawmakers and state attorneys general over the appeal of its nicotine products to teenagers. Thursday's move, which ends online sales, means Juul's mango, fruit, creme and cucumber nicotine pod flavors will no longer be available for sale anywhere in the United States. Juul's new chief executive, K.C. Crosthwaite, a veteran of Marlboro maker Altria Group Inc, announced the move Thursday as the company attempts to repair its relationship with regulators.
Altria Group, Inc. will host a live audio webcast on Thursday, October 31, 2019, at 9:00 a.m. Eastern Time to discuss its 2019 third-quarter business results. Altria will issue a press release containing its business results at approximately 7:00 a.m.
Cigarette maker Philip Morris reported better-than-expected third-quarter earnings Thursday. The stock was up in premarket trading, but fell after management provided disappointing fourth quarter guidance on the company’s earnings conference call.
Investing.com – E-cigarette company Juul Labs will no longer sell sweet and fruity e-cigarette refill pods online, news reports said Thursday.
NEW YORK, Oct. 17, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
Juul Labs will cease US online sales of its fruity-flavoured e-cigarette pods as it battles a “lack of trust” and pressure from regulators over the health effects of vaping. Pending a review from the Food and Drug Administration, Juul said on Thursday it was suspending sales of its non-tobacco-, non-menthol-based flavours in the US. The start-up acknowledged “the lack of trust in our industry” and said it regarded the Food and Drug Administration’s practices were the best way to determine what role its products could play in helping wean adult smokers off traditional cigarettes, while also keeping them away from minors.
NEW ORLEANS, Oct. 16, 2019 -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:.
CEDARHURST, NY / ACCESSWIRE / October 16, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.
NEW YORK, NY / ACCESSWIRE / October 16, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Altria Group, Inc. ("Altria" or the "Company") ...